Magnani Lab
Cancer Immunotherapy and Cell Engineering
Our research focuses on immunotherapy and uses genetic engineering to unleash our immune system against cancer. We apply non-viral engineering to design next-generation CAR T cells with the aim of providing solutions to some relevant challenges in the field, including cumbersome manufacturing, disease resistance, and hostile microenvironment.
Research Interests
Our research seeks to develop new cancer treatments, specifically CAR T-cell immunotherapy. The idea is to unleash our immune system against cancer. To this end, blood cells are weaponized through the use of genetic engineering and become living drugs. These therapies are personalized for each patient. Specifically, T cells are collected from the patient's blood, genetically engineered in the lab and infused back into our patient. Now T cells have a new receptor, called chimeric antigen receptor or CAR, which allows cancer cell recognition and T cell activation.